Rapid repurposing of existing drugs as new therapeutics for COVID-19 has been an important strategy in the management of disease severity during the ongoing SARS-CoV-2 pandemic. Here, we screened by high-throughput docking 6,000 compounds within the DrugBank library for their potential to bind and inhibit the SARS-CoV-2 3CL main protease, a chymotrypsin-like enzyme that is essential for viral replication. For 19 candidate hits, parallel in vitro fluorescence-based protease-inhibition assays and Vero-CCL81 cell-based SARS-CoV-2 replication-inhibition assays were performed. One hit, diclazuril (an investigational anti-protozoal compound), was validated as a SARS-CoV-2 3CL main protease inhibitor in vitro (IC50 value of 29 μM) and modestly inhibited SARS-CoV-2 replication in Vero-CCL81 cells. Another hit, lenvatinib (approved for use in humans as an anti-cancer treatment), could not be validated as a SARS-CoV-2 3CL main protease inhibitor in vitro, but serendipitously exhibited a striking functional synergy with the approved nucleoside analogue remdesivir to inhibit SARS-CoV-2 replication in Vero-CCL81 cells. Lenvatinib is a broadly-acting host receptor tyrosine kinase (RTK) inhibitor, but the synergistic effect with remdesivir was not observed with other approved RTK inhibitors (such as pazopanib or sunitinib), suggesting that the mechanism-of-action is independent of host RTKs. Furthermore, time-of-addition studies revealed that lenvatinib/remdesivir synergy probably targets SARS-CoV-2 replication subsequent to host-cell entry. Our study shows that combining computational and cellular screening is an efficient means to identify existing drugs with repurposing potential as antiviral compounds. Future studies should aim at understanding and optimizing the lenvatinib/remdesivir synergistic mechanism as a therapeutic option.IMPORTANCESuccessful repurposing of existing drugs as COVID-19 therapeutics would be a rapid and important means to limit disease severity during the SARS-CoV-2 pandemic. In this study, we used a computational screening approach to identify existing drugs that might inhibit the function of a critical enzyme (the 3CL main protease) encoded by the causative agent of COVID-19, SARS-CoV-2. While we found that diclazuril (an investigational human drug already approved for use in animals) inhibited this viral enzyme in vitro, it only showed modest ability to inhibit SARS-CoV-2 replication in cells. However, our approach serendipitously identified lenvatinib (an anti-cancer drug approved for use in humans) as a potent inhibitor of SARS-CoV-2 replication when combined with the existing approved antiviral drug, remdesivir. Our findings raise the possibility that future studies to understand the molecular mechanisms underlying the lenvatinib/remdesivir synergy could uncover new therapeutic principles for treatment of COVID-19 or similar viral diseases.